PR92139

EAST RUTHERFORD, N.J., Oct. 7, 2021 /PRNewswire=KYODO JBN/ --

Cambrex today announced that it is expanding its manufacturing center of

excellence in High Point, NC. The $30+ million investment is designed to meet

the continually growing demand for small molecule development and manufacturing

services.

The expansion will add new chemistry laboratories, two new clinical

manufacturing suites and include a small-scale commercial manufacturing

operation with three work centers and 2,000 Litre reactors.

This investment will provide Cambrex with the capabilities to handle the latest

R&D process research tools and techniques, increase Cambrex's equipment

offerings to support customer's speed to market goals, and provide a dedicated

facility for orphan drugs and niche therapies (annual volumes <500kg).

Alongside the new infrastructure which focuses on energy savings and

efficiency, 78 new jobs will be created in the area.  New positions include

operations, scientists, quality assurance and administrative personnel.

"Cambrex's mission is to support our pharmaceutical customers in the

development and manufacturing of new therapies that improve human health," said

Thomas Loewald, Cambrex CEO.  "As a result of our High Point team's commitment

to providing our customers best-in-class technical expertise, innovative

chemistry, and engineering solutions, the facility has seen rapid growth in

demand for our development and manufacturing services.  We are extremely

excited about this expansion in North Carolina, which would not have been

possible without the support of the State's leadership and economic development

programs, and their focus on nurturing the region's skilled and diverse

workforce."

A performance-based grant of $200,000 from the One North Carolina Fund will

help with Cambrex's expansion. The One North Carolina Fund provides financial

assistance to local governments to help attract economic investment and to

create jobs.

About Cambrex

Cambrex is the leading small molecule company that provides drug substance,

drug product, and analytical services across the entire drug lifecycle. The

company provides customers with an end-to-end partnership for the research,

development, and manufacture of small molecule therapeutics. With over 40

years' experience and a growing team of over 2,200 experts servicing global

clients from sites in North America and Europe, Cambrex is a trusted partner in

branded and generic markets for API and dosage form development and

manufacturing.

Cambrex offers a range of specialist drug substance technologies and

capabilities, including biocatalysis, continuous flow, controlled substances,

solid state science, material characterization, and highly potent APIs. In

addition, Cambrex can support conventional dosage forms, including oral solids,

semi-solids, and liquids, and has the expertise to manufacture specialist

dosage forms such as modified-release, fixed-dose combination, pediatric,

bi-layer tablets, stick packs, topicals, controlled substances, sterile and

non-sterile ointments.

For more information, visit www.cambrex.com

Contact:   Natalee Campbell

Email:     press@cambrex.com

Phone:     +1 919 544 8638

Logo  - https://mma.prnewswire.com/media/1198585/Cambrex_Logo.jpg

Source:  Cambrex